Skip to main content
Erschienen in: Journal of Neural Transmission 2/2009

01.02.2009 | Alzheimer's Disease and Related Disorders - Original Article

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

verfasst von: Volker Welge, Oliver Fiege, Piotr Lewczuk, Brit Mollenhauer, Hermann Esselmann, Hans-Wolfgang Klafki, Stefanie Wolf, Claudia Trenkwalder, Markus Otto, Johannes Kornhuber, Jens Wiltfang, Mirko Bibl

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer’s disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Aβ1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Aβ1-42/Aβ1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Aβ1-42/Aβ1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Aβ1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Aβ1-42/Aβ1-38. The ratio Aβ1-42/Aβ1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.
Literatur
Zurück zum Zitat Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006a) CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMedCrossRef Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006a) CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187PubMedCrossRef
Zurück zum Zitat Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006b) CSF diagnosis of Alzheimer’s disease and dementias with Lewy bodies. J Neural Transm 113:1771–1778PubMedCrossRef Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006b) CSF diagnosis of Alzheimer’s disease and dementias with Lewy bodies. J Neural Transm 113:1771–1778PubMedCrossRef
Zurück zum Zitat Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J (2007a) Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol Psy 12:671–680CrossRef Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J (2007a) Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol Psy 12:671–680CrossRef
Zurück zum Zitat Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J (2007b) Reduced CSF carboxyterminally truncated Aβ petides in frontotemporal lobe degenerations. J Neural Transm 114:621–628PubMedCrossRef Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J (2007b) Reduced CSF carboxyterminally truncated Aβ petides in frontotemporal lobe degenerations. J Neural Transm 114:621–628PubMedCrossRef
Zurück zum Zitat Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang J (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides. Electrophoresis 25:2912–2918PubMedCrossRef Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang J (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides. Electrophoresis 25:2912–2918PubMedCrossRef
Zurück zum Zitat Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, Gross M, Falkai P, Kornhuber J, Wiltfang J (2008a) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord 25:256–265PubMedCrossRef Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, Gross M, Falkai P, Kornhuber J, Wiltfang J (2008a) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord 25:256–265PubMedCrossRef
Zurück zum Zitat Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J (2008b) CSF amyloid-β 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl 2:1548–1556CrossRef Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J (2008b) CSF amyloid-β 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl 2:1548–1556CrossRef
Zurück zum Zitat Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx. 1:213–225PubMedCrossRef Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx. 1:213–225PubMedCrossRef
Zurück zum Zitat De Jong D, Jansen RWMM, Kremer BPH, Verbeek MM (2006) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61:755–758PubMed De Jong D, Jansen RWMM, Kremer BPH, Verbeek MM (2006) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61:755–758PubMed
Zurück zum Zitat Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752PubMedCrossRef Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752PubMedCrossRef
Zurück zum Zitat Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890PubMedCrossRef Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890PubMedCrossRef
Zurück zum Zitat Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer’s disease—a comparative study. Arch Gen Psychiatry 61:95–102PubMedCrossRef Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer’s disease—a comparative study. Arch Gen Psychiatry 61:95–102PubMedCrossRef
Zurück zum Zitat Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD-patients using ß-amyloid (1-42) and tau levels in CSF. Neurology 52:1555–1562PubMed Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD-patients using ß-amyloid (1-42) and tau levels in CSF. Neurology 52:1555–1562PubMed
Zurück zum Zitat Ishikawa M (2004) Guideline committee for idiopathic normal pressure hydrocephalus, Japanese society of normal pressure hydrocephalus. Neurol Med Chir 44:222–223CrossRef Ishikawa M (2004) Guideline committee for idiopathic normal pressure hydrocephalus, Japanese society of normal pressure hydrocephalus. Neurol Med Chir 44:222–223CrossRef
Zurück zum Zitat Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mitsushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 44:17–26PubMedCrossRef Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mitsushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 44:17–26PubMedCrossRef
Zurück zum Zitat Lee VMY, Balin BJ, Otvos L, Trojanowski JQ (1991) A68. A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251:675–678PubMedCrossRef Lee VMY, Balin BJ, Otvos L, Trojanowski JQ (1991) A68. A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251:675–678PubMedCrossRef
Zurück zum Zitat Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin Chem 52:332–334PubMedCrossRef Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin Chem 52:332–334PubMedCrossRef
Zurück zum Zitat Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta 42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25:273–281PubMedCrossRef Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta 42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25:273–281PubMedCrossRef
Zurück zum Zitat Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Rüther E, Kornhuber J, Wiltfang J (2003) The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun Mass Spectrom 17:1291–1296PubMedCrossRef Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Rüther E, Kornhuber J, Wiltfang J (2003) The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun Mass Spectrom 17:1291–1296PubMedCrossRef
Zurück zum Zitat Litvan I (1997) Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin Neurol 6:167–185PubMed Litvan I (1997) Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin Neurol 6:167–185PubMed
Zurück zum Zitat Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. Arch Neurol 60:1202–1206PubMedCrossRef Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. Arch Neurol 60:1202–1206PubMedCrossRef
Zurück zum Zitat McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed
Zurück zum Zitat McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed
Zurück zum Zitat Mehta PD, Pirttila T (2005) Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer’s disease. Neurodegener Dis 2:242–245PubMedCrossRef Mehta PD, Pirttila T (2005) Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer’s disease. Neurodegener Dis 2:242–245PubMedCrossRef
Zurück zum Zitat Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38:643–648PubMedCrossRef Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38:643–648PubMedCrossRef
Zurück zum Zitat Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedmann M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMed Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedmann M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMed
Zurück zum Zitat Oslin D, Aktinsson RM, Smith DM, Hendrie H (1998) Alcohol related dementia: proposed clinical criteria. Int J Ger Psychiatry 13:203–212CrossRef Oslin D, Aktinsson RM, Smith DM, Hendrie H (1998) Alcohol related dementia: proposed clinical criteria. Int J Ger Psychiatry 13:203–212CrossRef
Zurück zum Zitat Roman GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masedeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 43:243–245 Roman GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masedeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 43:243–245
Zurück zum Zitat Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD (2005) Amyloid β 38, 40 and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 58:139–142PubMedCrossRef Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD (2005) Amyloid β 38, 40 and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 58:139–142PubMedCrossRef
Zurück zum Zitat Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamuro T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S (1998) Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci 158:134–140PubMedCrossRef Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamuro T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S (1998) Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci 158:134–140PubMedCrossRef
Zurück zum Zitat Shoji M, Matsubara E, Kanai M, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2000) Taps to Alzheimer’s patients: a continuous Japanese study of cerebrospinal fluid biomarkers. Ann Neurol 48:402PubMedCrossRef Shoji M, Matsubara E, Kanai M, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2000) Taps to Alzheimer’s patients: a continuous Japanese study of cerebrospinal fluid biomarkers. Ann Neurol 48:402PubMedCrossRef
Zurück zum Zitat Shoji M, Kanai M (2001) Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness. J Alzheimers Dis 25:273–281 Shoji M, Kanai M (2001) Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness. J Alzheimers Dis 25:273–281
Zurück zum Zitat Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2001) The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently. Neurobiol Aging 22:209–215PubMedCrossRef Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2001) The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently. Neurobiol Aging 22:209–215PubMedCrossRef
Zurück zum Zitat Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49–52PubMedCrossRef Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49–52PubMedCrossRef
Zurück zum Zitat Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216PubMedCrossRef Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216PubMedCrossRef
Zurück zum Zitat WHO: World Health Organisation (1998) Human transmissible spongiform encephalopathy. Wkly Epidemiol Rec 73:361–365 WHO: World Health Organisation (1998) Human transmissible spongiform encephalopathy. Wkly Epidemiol Rec 73:361–365
Zurück zum Zitat Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-tau in patients with low- and high-CSF Aβ40 load. J Neurochem 101:1053–1059PubMedCrossRef Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-tau in patients with low- and high-CSF Aβ40 load. J Neurochem 101:1053–1059PubMedCrossRef
Zurück zum Zitat Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Anneart W, De Strooper B, Saftig P (2001) Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells. J Biol Chem 276:42645–42657PubMedCrossRef Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Anneart W, De Strooper B, Saftig P (2001) Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells. J Biol Chem 276:42645–42657PubMedCrossRef
Zurück zum Zitat Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and patients with chronic neuroinflammation. J Neurochem. 81:481–496PubMedCrossRef Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and patients with chronic neuroinflammation. J Neurochem. 81:481–496PubMedCrossRef
Zurück zum Zitat World Medical Organisation (1996) Declaration of Helsinki. Br Med J 313:1448–1449 World Medical Organisation (1996) Declaration of Helsinki. Br Med J 313:1448–1449
Metadaten
Titel
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
verfasst von
Volker Welge
Oliver Fiege
Piotr Lewczuk
Brit Mollenhauer
Hermann Esselmann
Hans-Wolfgang Klafki
Stefanie Wolf
Claudia Trenkwalder
Markus Otto
Johannes Kornhuber
Jens Wiltfang
Mirko Bibl
Publikationsdatum
01.02.2009
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 2/2009
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-008-0177-6

Weitere Artikel der Ausgabe 2/2009

Journal of Neural Transmission 2/2009 Zur Ausgabe

Parkinson's Disease and Allied Conditions - Short Communication

Acquired stuttering after pallidal deep brain stimulation for dystonia

Parkinson's Disease and Allied Conditions - Original Article

MEG resting state functional connectivity in Parkinson’s disease related dementia

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.